Protein Delivery by Peptide-Based Stealth Liposomes: A Biomolecular Insight into Enzyme Replacement Therapy.
Cells, Cultured
Drug Compounding
/ methods
Drug Liberation
Enzyme Assays
Enzyme Replacement Therapy
/ methods
Fibroblasts
Humans
Liposomes
Membrane Proteins
/ administration & dosage
Nanoparticles
/ chemistry
Neuronal Ceroid-Lipofuscinoses
/ drug therapy
Peptides
/ chemistry
Primary Cell Culture
Thiolester Hydrolases
/ administration & dosage
blood brain barrier (BBB)
enzyme replacement therapy (ERT)
liposomes
lysosomal storage disorders (LSDs)
peptide aptamers
Journal
Molecular pharmaceutics
ISSN: 1543-8392
Titre abrégé: Mol Pharm
Pays: United States
ID NLM: 101197791
Informations de publication
Date de publication:
07 12 2020
07 12 2020
Historique:
pubmed:
29
10
2020
medline:
18
9
2021
entrez:
28
10
2020
Statut:
ppublish
Résumé
Infantile neural ceroid lipofuscinosis (INCL) is a lysosomal storage disorder characterized by mutations in the
Identifiants
pubmed: 33112630
doi: 10.1021/acs.molpharmaceut.0c00615
doi:
Substances chimiques
Liposomes
0
Membrane Proteins
0
Peptides
0
Thiolester Hydrolases
EC 3.1.2.-
PPT1 protein, human
EC 3.1.2.22
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM